Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.53 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.44 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.44 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.44 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | CACNA1E | Q15878 | 1/20 | 0.44 |
| ▸ | CACNA2D4 | Q7Z3S7 | 1/20 | 0.44 |
| ▸ | CACNA2D3 | Q8IZS8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602342 | 0.86 | GPR119 (0.39) | GPR119 | |
| SCHEMBL27111204 | 0.85 | GPR119 (0.56) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL29826100 | 0.85 | GPR119 (0.56) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL3602166 | 0.85 | GPR119 (0.49) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL31058712 | 0.84 | GPR119 (0.52) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL3612412 | 0.84 | GPR119 (0.52) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL1556569 | 0.84 | GPR119 (0.48) | GPR119 | |
| SCHEMBL29826835 | 0.83 | GPR119 (0.54) | GPR119 | |
| SCHEMBL25113770 | 0.82 | GPR119 (0.50) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL5265313 | 0.80 | GPR119 (0.56) | GPR119CACNB4CACNA1ACACNA1GCACNG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-2121703-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | GPR119 1/4885CACNB4 1176/4885CACNA1A 198/4885 |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | GPR119 4/4885CACNB4 3141/4885CACNA1A 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.